Cargando…

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test

BACKGROUND: Serum YKL-40 is an inflammatory biomarker associated with disease activity and mortality in diseases characterized by inflammation such as coronary artery disease (CAD). Exercise has a positive effect on CAD, possibly mediated by a decreased inflammatory activity. This study aimed to com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dam Mygind, Naja, Axelsson, Anna, Ruwald, Martin H., Dalsgaard, Morten, Steffensen, Rolf, Iversen, Kasper, Johansen, Julia S., Kastrup, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367501/ https://www.ncbi.nlm.nih.gov/pubmed/28392973 http://dx.doi.org/10.1097/XCE.0000000000000073

Ejemplares similares

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality – a cohort study
por: Sørensen, Allan Klitgaard, et al.
Publicado: (2015)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Cardiac Magnetic Resonance Imaging used for Evaluation of Adipose-Derived Stromal Cell Therapy in Patients with Chronic Ischemic Heart Disease
por: Qayyum, Abbas Ali, et al.
Publicado: (2019)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Echocardiographic predictors of exercise capacity and mortality in chronic obstructive pulmonary disease
por: Schoos, Mikkel Malby, et al.
Publicado: (2013)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects
por: Nielsen, Kaspar R, et al.
Publicado: (2011)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
por: Gevezova, Maria, et al.
Publicado: (2023)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
por: Shao, Rong, et al.
Publicado: (2009)

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis
por: Shao, Rong
Publicado: (2013)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model
por: Kocabas, Rahim
Publicado: (2023)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice
por: Salamon, Johannes, et al.
Publicado: (2014)

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction
por: Schroder, Jakob, et al.
Publicado: (2019)

A polymorphism associated with increased levels of YKL-40 and the risk of early onset of lone atrial fibrillation
por: Henningsen, Kristoffer M A, et al.
Publicado: (2013)

Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
por: Kim, Steve H, et al.
Publicado: (2007)

YKL-40 levels are independently associated with albuminuria in type 2 diabetes
por: Røndbjerg, Anne K, et al.
Publicado: (2011)

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension
por: Wang, Dong, et al.
Publicado: (2012)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

CTX-II and YKL-40 in early diagnosis and treatment evaluation of osteoarthritis
por: Wang, Pengkun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jh91hlc9hr01ue453f951vg9j3